What Restricts the Clinical Use of Nicotinic Acid?

Author(s): Anastazia Kei, Evangelos N. Liberopoulos, Moses S. Elisaf

Journal Name: Current Vascular Pharmacology

Volume 9 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


Nicotinic acid is the oldest hypolipidemic agent in use, since 1955. It possesses broad-spectrum lipidmodifying properties including reduction of total cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. In addition, nicotinic acid is the most potent available hypolipidemic agent for increasing plasma high density lipoprotein (HDL) cholesterol and decreasing lipoprotein (a) levels. Clinical trials have demonstrated that nicotinic acid can decrease cardiovascular morbidity and mortality. However, nicotinic acid is underused in the clinical setting due to its high rate of side effects, including flushing, gastrointestinal disorders, rash, hyperglycemia and hyperuricemia. The nicotinic acid-associated side effects and their management are the focus of this review.

Keywords: Adverse events, niacin, nicotinic acid, side effects, toxicity, laropiprant, high density lipoprotein, gastrointestinal disorders, flushing, rash

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [521 - 530]
Pages: 10
DOI: 10.2174/157016111796197215
Price: $65

Article Metrics

PDF: 17